|Bid||0.0000 x 39400|
|Ask||1.1600 x 1000|
|Day's Range||1.0800 - 1.1900|
|52 Week Range||0.9400 - 3.0400|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018 º 2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018 º 2Q 2019 Collaboration and Services Revenue was.
WESTLAKE VILLAGE, Calif., Aug. 05, 2019 -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to.
MannKind Corporation (MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 7, 2019. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.
MannKind Corporation (MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now enrolling children 4-7 years of age (Cohort 3) and nearing completion for Cohort 2 (8-12 years of age). An interim review of data from individuals participating in the second cohort shows that the single‑dose pharmacokinetic profile of insulin levels for this age group is consistent with the pattern seen in adults. In addition, dosing over one month demonstrated a safety profile that was also consistent with that observed in adults. As a result of these findings, MannKind and the study investigators are proceeding with enrollment of the third cohort of subjects.
WESTLAKE VILLAGE, Calif., July 18, 2019 -- MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0.
WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin.
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.
WESTLAKE VILLAGE, Calif., June 12, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.
MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California. MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10. This study is the first step in preparation for a phase 3 safety and efficacy study.
Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA).
MannKind Corporation (MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. "We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation.
1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net.
WESTLAKE VILLAGE, Calif., April 30, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management.
WESTLAKE VILLAGE, Calif., April 25, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. The presentation will be webcast live. To access the webcast, please visit www.hcwevents.com. Interested parties can also access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
MannKind Corporation (MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associate sponsor of Andretti Autosport for this race and will partner with Daly on his No. 25 U.S. Air Force Honda.
CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Advaxis Inc (ADXS), and MannKind Corporation (MNKD) are 4 healthcare companies raising the bar on Wednesday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.
Conference Call to Begin Today at 9:00 AM ET 4Q 2018 Total Revenues were $16.0 million; 254% growth vs. 4Q 2017 4Q 2018 Afrezza Net Revenue was $5.7 million; 28% growth vs. 4Q.
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / MannKind Corporation (NASDAQ: MNKD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 9:00 ...
WESTLAKE VILLAGE, Calif., Feb. 20, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation.
WESTLAKE VILLAGE, Calif., Feb. 20, 2019 -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.
WESTLAKE VILLAGE, Calif., Feb. 19, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019.
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold ...